Blocking Connexin-43 may improve diabetic retinopathy, AMDFebruary 11th 2022
Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
BREAKING NEWS: Faricimab approved by U.S. FDA for treatment of wet AMD, DMOJanuary 29th 2022
Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
Retinal age gap linked to heightened death risk, study findsJanuary 21st 2022
The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.
Inflammation link discovered between lupus and macular degenerationJanuary 7th 2022
Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.
Drug delivery to retina via port delivery system is efficient for patients with wet AMDNovember 15th 2021
In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Mark Wieland noted that the port delivery system with ranibizumab provides drug delivery over an extended period.
DMO: Study finds faricimab provides sustained retinal stabilityNovember 14th 2021
During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.